FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to medicine and describes a pharmaceutical combined aerosol composition of a propellant type of protein oligopeptide or polypeptide compounds from a group of proteolytic enzyme inhibitors with an antiviral, antimicrobial or anti-inflammatory substance taken in a solution with water content of not more than 10 % of the volume of the composition and total amount of said active substances 0.001–50 mg per 1 ml of the composition. Composition also contains ingredients of the buoyancy mixture - glycerol, ethanol and ozone-saving water-insoluble propellant, taken in volume ratio 0.01–40:0.01–7.99:50.0–99.7 %, respectively, on the volume of the composition. Pharmaceutical composition is obtained by step-by-step mixing of said active substances with each successive ingredient of the ejection mixture, namely: glycerol, ethanol and ozone-saving water-insoluble propellent.
EFFECT: invention provides a pharmaceutical aerosol formulation which enables to preserve the propellent properties and biological functions of the active substances; created aerosol composition can be used in treating diseases accompanied by proteolytic balance disorders.
10 cl, 6 dwg, 5 tbl, 10 ex
Authors
Dates
2020-01-15—Published
2015-06-15—Filed